Hydroxychloroquine Sulphate Market

The Hydroxychloroquine Sulphate market is projected to grow at a CAGR of 4.8% from 2025 to 2035, supported by its established role in the treatment of autoimmune diseases, including rheumatoid arthritis, lupus erythematosus, and malaria prophylaxis.

Hydroxychloroquine Sulphate is a synthetic antimalarial and immunomodulatory agent that reduces inflammation and modulates immune system activity. It functions by interfering with lysosomal activity and antigen presentation in immune cells, making it effective in managing autoimmune disorders. While it gained significant attention during the COVID-19 pandemic, its core usage remains in chronic inflammatory and autoimmune conditions.

Market growth is fueled by increasing diagnosis rates of autoimmune diseases, ongoing clinical research on its immunomodulatory effects, and consistent global demand for affordable and effective long-term therapies. Its oral administration and relatively favorable safety profile contribute to its wide use in both hospital and outpatient settings.

North America leads the Hydroxychloroquine Sulphate market, driven by a high prevalence of autoimmune disorders, a strong pharmaceutical supply chain, and regular use in chronic disease management.

Europe holds a significant share, particularly in countries like Germany, France, and the UK, where structured rheumatology care and autoimmune disease registries support sustained demand.

The Asia-Pacific region is expected to grow the fastest, owing to increasing access to rheumatology care, rising awareness of autoimmune conditions, and broadening healthcare infrastructure in nations like India, China, and Indonesia.

Latin America and the Middle East & Africa are witnessing steady expansion, aided by WHO-supported malaria control programs, growing awareness of lupus and rheumatoid arthritis, and improved availability of generic hydroxychloroquine formulations.